- Details
- Dong-Woo Kang joins Andrea Miyahira to discuss his team’s research on high-intensity interval training in prostate cancer patients undergoing active surveillance. The study examines the effects of a 12-week supervised aerobic exercise program on cardiometabolic biomarkers and cancer-related outcomes. The conversation highlights significant findings, including improvements in PSA levels, cancer cel...
|
- Details
- Andrea Miyahira hosts Steven Kregel to discuss a published paper on humanized mouse models for metastatic prostate cancer. Dr. Kregel discusses the challenges of modeling prostate cancer in mice and introduces humanized mouse models that better recapitulate human immune responses. He explains how these models, developed using human hematopoietic stem cells, allow for the study of cancer therapies...
|
- Details
- Nonna Shakhnazaryan discusses a phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting CD46, in combination with enzalutamide for metastatic castration-resistant prostate cancer. The study establishes the maximally tolerated dose and shows promising results, with 71% of patients experiencing PSA declines, including some who previously progressed on enzalutamide. The med...
|
- Details
- Andrea Miyahira discusses with Irene Casanova-Salas and Joaquin Mateo a Cancer Cell publication on using circulating tumor extracellular vesicles (EVs) to monitor metastatic prostate cancer evolution. The researchers describe their novel method for analyzing both DNA and RNA from EVs in patient plasma samples. They highlight the advantages of EV analysis over traditional ctDNA, including the abili...
|
- Details
- Andrea Miyahira interviews Abhijit Parolia about his group's study on NSD2's role in prostate cancer. Dr. Parolia explains how NSD2, a histone methyltransferase, reprograms androgen receptor (AR) activity in prostate cancer cells. The research reveals that NSD2 is upregulated in malignant prostate tissue and is crucial for AR binding to chimeric AR-FOXA1 sites, promoting tumor growth. Using CRISPR...
|
- Details
- Veda Giri discusses her roles as director of the Cancer Genetics and Prevention Program and the Early-Onset Cancer Program at Yale Cancer Center, highlighting her path through medical school, where her interest in genetics and patient care deepened. Her career was significantly shaped by mentors and opportunities that arose during her residency and fellowships, emphasizing the importance of mentor...
|
- Details
- Alexandra Sokolova discusses her team's study on genomic alterations influencing the response to lutetium-177 PSMA in metastatic castration-resistant prostate cancer. Their research highlights the need for better biomarkers to predict patient outcomes with lutetium-177 PSMA, as not all patients respond to this treatment. Utilizing data from a collaborative database of over 2000 patients, Dr. Sokol...
|
- Details
- Andrea Miyahira speaks with Ulka Vaishampayan who shares insights into her leadership roles, including chairing the phase I team, co-leading the Translational Clinical Research Program, and serving as chief of Ambulatory Clinical Services. Her journey from lymphoma research to GU oncology was sparked by an early passion for clinical trials and a drive to address gaps in prostate, bladder, and kidn...
|
- Details
- Tanya Dorff discusses her team's Phase 1 trial on PSCA CAR T cell therapy for metastatic castration-resistant prostate cancer, published in Nature Medicine. Dr. Dorff highlights that prostate cancer's immunosuppressive environment poses significant challenges, making the development of potent therapies like CAR T cells crucial. The trial involved administering CAR T cells, initially without and th...
|
- Details
- Alicia Morgans speaks with Zach Klaassen about his research focusing on the intersection of mental health and prostate cancer care in the veterans’ population. Dr. Klaassen shares insights from his extensive study aimed at creating the world's largest prostate cancer mental health database. Initial findings reveal that veterans with mental health issues are less frequently diagnosed with prostate...
|
